Related Experiment Videos
Cutaneous vasculitis
1Division of Rheumatology, Immunology and Allergy, Georgetown University Medical Center, Washington, DC 20007-2197.
Insights
Defining and treating cutaneous vasculitis remains challenging due to inconsistent terminology and classification. Recent advancements in recombinant cytokines and growth factors show varied therapeutic potential for these vasculopathic processes.
Area of Science:
- Dermatology
- Immunology
- Pathophysiology
Background:
- Cutaneous vasculitis and vasculopathic processes present diagnostic and therapeutic challenges.
- Historical imprecision in terminology and classification complicates understanding.
- The presence or absence of systemic illness adds to the complexity.
Purpose of the Study:
- To clarify the definition, diagnosis, and treatment of cutaneous vasculitis.
- To reduce ambiguity by applying consistent diagnostic constraints and accepted terminology.
- To review recent case reports, basic science findings, and therapeutic applications.
Main Methods:
- Review of recent case reports and communications on cutaneous vasculitis.
- Analysis of basic science reports on underlying pathophysiology.
- Evaluation of therapeutic roles of recombinant cytokines, growth factors, and thrombolytics.
Main Results:
- Recent literature includes case reports and basic science findings on cutaneous vasculitis.
- Technological advances have yielded new therapeutic agents like recombinant cytokines.
- The efficacy of these agents in treating cutaneous vasculitis varies, with some showing provocative and others therapeutic effects.
Conclusions:
- Consistent terminology and diagnostic criteria are crucial for advancing the understanding and management of cutaneous vasculitis.
- New therapeutic agents show potential but require further investigation for optimal use.
- Continued research into pathophysiology and clinical applications is essential.
Abstract:
Cutaneous vasculitis and vasculopathic processes continue to be difficult to define, diagnose, and treat. Historically, the complexity of these disorders has been compounded by imprecision in terminology and classification and the presence or absence of underlying systemic illness. Approaching the literature with consistent diagnostic constraints and accepted terminology can, it is hoped, eliminate some of the ambiguity. During the past year, several case reports and brief communications regarding cutaneous vasculitis or vasculopathies have appeared, as well as thoughtful basic science reports whose authors have attempted to further the understanding of the underlying pathophysiology. Recent technologic advances have produced recombinant cytokines, growth factors, and thrombolytics that have been used therapeutically for a variety of medical illnesses. The role of these agents in the treatment of cutaneous vasculitis and vasculopathies has varied from provocative in some to therapeutic in others. A number of these reports are discussed.